Boris Schmidt researcher (ORCID 0000-0003-1662-2392)
Schmidt, Boris 1962-
VIAF ID: 4711159613658041030004 (Personal)
Permalink: http://viaf.org/viaf/4711159613658041030004
Preferred Forms
4xx's: Alternate Name Forms (2)
5xx's: Related Names (2)
Works
| Title | Sources |
|---|---|
| 3-[2,6-Bis(diethylcarbamoyl)pyridin-4-yl]-N-(tert-butoxycarbonyl)alanine methyl ester: a chiral tridentate ligand that causes a diastereomeric excess of its lanthanide complexes in solution. |
|
| Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites. |
|
| Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. |
|
| Angiotensin receptor type 1 blockade in astroglia decreases hypoxia-induced cell damage and TNF alpha release |
|
| Auf dem Weg zum Aflatoxin M1 und verwandten Strukturen durch homogene Katalyse |
|
| Biodistribution and Efficacy Studies of the Proteasome Inhibitor BSc2118 in a Mouse Melanoma Model |
|
| Biomimetika ihre Synthese durch Übergangsmetall-katalysierte Schlüsselreaktionen und ihre Anwendung |
|
| Bis(arylvinyl)pyrazines, -pyrimidines, and -pyridazines as imaging agents for tau fibrils and β-amyloid plaques in Alzheimer's disease models |
|
| Cell‐Based Optimization of Covalent Reversible Ketoamide Inhibitors Bridging the Unprimed to the Primed Site of the Proteasome β5 Subunit |
|
| Complexation of copper(II)-Chelidamate: A multifrequency-pulsed electron paramagnetic resonance and electron nuclear double resonance analysis |
|
| Computational & experimental evaluation of the structure/activity relationship of β-carbolines as DYRK1A inhibitors. |
|
| Conversion of the LXR-agonist TO-901317--from inverse to normal modulation of gamma-secretase by addition of a carboxylic acid and a lipophilic anchor. |
|
| Copper dipicolinates as peptidomimetic ligands for the Src SH2 domain |
|
| Curcumin cross-links cystic fibrosis transmembrane conductance regulator (CFTR) polypeptides and potentiates CFTR channel activity by distinct mechanisms |
|
| Curcumin derivatives inhibit or modulate beta-amyloid precursor protein metabolism. |
|
| Curcumin-derived pyrazoles and isoxazoles: Swiss army knives or blunt tools for Alzheimer's disease? |
|
| Design and Synthesis of macrocyclic FKBP51 ligands |
|
| Design, Synthese und biologische Evaluierung von neuartigen FKBP51 Liganden |
|
| Design, Synthesis and Evaluation of Reversible and Covalent Binding Serine-Targeted LRRK2 Inhibitors |
|
| Design und Synthese selektiver Nek1 Inhibitoren |
|
| Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers |
|
| Discovery and Biological Evaluation of Potent and Selective N-Methylene Saccharin-Derived Inhibitors for Rhomboid Intramembrane Proteases. |
|
| Discovery and validation of 2-styryl substituted benzoxazin-4-ones as a novel scaffold for rhomboid protease inhibitors. |
|
| A disintegrin and metalloproteinase 17 (ADAM17) mediates inflammation-induced shedding of syndecan-1 and -4 by lung epithelial cells |
|
| DOCKTITE-a highly versatile step-by-step workflow for covalent docking and virtual screening in the molecular operating environment. |
|
| Drug development and PET-diagnostics for Alzheimer's disease. |
|
| Dysfunction of Somatostatin-Positive Interneurons Associated with Memory Deficits in an Alzheimer's Disease Model. |
|
| Elastase-like Activity Is Dominant to Chymotrypsin-like Activity in 20S Proteasome's β5 Catalytic Subunit. |
|
| Ensemble-Docking Approach on BACE-1: Pharmacophore Perception and Guidelines for Drug Design |
|
| An evolutionary recent neuroepithelial cell adhesion function of huntingtin implicates ADAM10-Ncadherin |
|
| EXP3179 inhibits collagen-dependent platelet activation via glycoprotein receptor-VI independent of AT1-receptor antagonism: potential impact on atherothrombosis. |
|
| Fc Antigen-bindende Fragment-Wirkstoff Konjugate als neues Antikörper-basiertes Format für den zielgerichteten Wirkstofftransport |
|
| Fc Antigen-Binding Fragment Drug Conjugates as Novel Antibody-Based Format for Targeted Drug Delivery |
|
| Fluorescent rhodanine-3-acetic acids visualize neurofibrillary tangles in Alzheimer's disease brains. |
|
| Fmoc protected peptide mimetic based on a cyclohexane framework and incorporation into angiotensin II |
|
| A frame shifted disulfide bridged analogue of angiotensin II |
|
| Functional role of matrix metalloproteinase-8 in stem/progenitor cell migration and their recruitment into atherosclerotic lesions |
|
| Immunotherapy alleviates amyloid-associated synaptic pathology in an Alzheimer's disease mouse model |
|
| Improved synthesis of ADAM10 inhibitor GI254023X. |
|
| In silico design, synthesis and evaluation of kinase and proteasome inhibitors as well as fluorescent probes. |
|
| In vivo imaging reveals sigmoidal growth kinetic of β-amyloid plaques. |
|
| Inhibition of gamma-secretase by the CK1 inhibitor IC261 does not depend on CK1delta. |
|
| Lipid bilayer position and orientation of novel carprofens, modulators of γ-secretase in Alzheimer's disease |
|
| Long-term in vivo imaging of fibrillar tau in the retina of P301S transgenic mice |
|
| Matrix metalloproteinase-8 promotes vascular smooth muscle cell proliferation and neointima formation. |
|
| Membrane anchoring γ-secretase modulators with terpene-derived moieties |
|
| Memory trace interference impairs recall in a mouse model of Alzheimer's disease |
|
| Methyltrioxorhenium - from oxidation and cyclopropanation to metathesis |
|
| Modification of a promiscuous inhibitor shifts the inhibition from γ-secretase to FLT-3. |
|
| Mutation-specific dual potentiators maximize rescue of CFTR gating mutants |
|
| N'-benzylidene-benzohydrazides as novel and selective tau-PHF ligands |
|
| Naturstoffe als Kinase-Inhibitoren: Totalsynthese, In-vitro-Kinase-Aktivität, In-vivo-Toxikologie in Zebrafisch-Embryonen und In-silico-Docking |
|
| NSAID-derived γ-secretase modulation requires an acidic moiety on the carbazole scaffold. |
|
| Phenylthiazolyl-hydrazide and its derivatives are potent inhibitors of tau aggregation and toxicity in vitro and in cells |
|
| Proteasome inhibition potentiates Kv1.3 potassium channel expression as therapeutic target in drug-sensitive and -resistant human melanoma cells |
|
| Regulation of peroxisome proliferator-activated receptor gamma activity by losartan metabolites |
|
| Screening for inhibitors of tau protein aggregation into Alzheimer paired helical filaments: a ligand based approach results in successful scaffold hopping |
|
| Small-Molecule Inhibitors of GSK-3: Structural Insights and Their Application to Alzheimer's Disease Models |
|
| Soluble CD23 controls IgE synthesis and homeostasis in human B cells. |
|
| Structure-based optimization of oxadiazole-based GSK-3 inhibitors. |
|
| Strukturbasiertes Design, Synthese und pharmakologische Evaluation von Proteasom- und FLT3-Inhibitoren in Leukämiemodellen |
|
| Substrate-targeting gamma-secretase modulators |
|
| Synthesis and biological evaluation of glycogen synthase kinase 3 (GSK-3) inhibitors: an fast and atom efficient access to 1-aryl-3-benzylureas. |
|
| Synthesis of methoxy-X04 derivatives and their evaluation in Alzheimer's disease pathology. |
|
| Synthesis of tetramic and tetronic acids as beta-secretase inhibitors. |
|
| Therapeutic effects of angiotensin (AT1) receptor antagonists: potential contribution of mechanisms other than AT1 receptor blockade |
|
| Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations |
|
